Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin, MEI Drop PI3Kδ Inhibitor Outside Japan after US FDA Guidance
December 7, 2022
- Francis Vaillant to Succeed Shingo Iwamoto as Sandoz Japan President
December 7, 2022
- Kyowa Kirin Rolls Out Automated Injection Device of G-Lasta in Japan
December 7, 2022
- Ono Gets Its Hands on Equillium’s Rights to 1st-in-Class CD6 Drug
December 7, 2022
- Opdivo Tops Japan Drug Sales Ranking for 11 Months on End: Encise
December 7, 2022
- Yukinari Kono Named as Chief of Baxter Japan
December 6, 2022
- PeptiDream, RayzeBio Pick 1st Peptide Radiopharmaceutical Candidate
December 6, 2022
- Keytruda Filed in Japan for Primary Mediastinal Large B-Cell Lymphoma
December 6, 2022
- Deloitte Proposal to Shed Number of Generics Aims to Spur Industry Consolidation
December 5, 2022
- Mochida Set to Market Lilly’s Ulcerative Colitis Drug Candidate in Japan
December 5, 2022
- 2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan
December 2, 2022
- Twymeeg Tops GP Promotion Ranking for 3 Months Running in September: Intage
December 2, 2022
- Healios to Provide Universal Donor Cells to Sumitomo
December 2, 2022
- Mochida Obtains Japan Marketing Rights for Ferring’s Ulcerative Colitis Drug
December 2, 2022
- Taisho’s Nanozora, 1st Nanobody Agent in Japan, Now Available
December 2, 2022
- AstraZeneca Japan Set to Buttress Respiratory Business with Tezspire Debut
December 2, 2022
- Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
December 1, 2022
- Moderna Inks Digital Transformation Pact with Japanese Health Tech
December 1, 2022
- Novartis Rolls Out Cosentyx 300 mg Pen in Japan
December 1, 2022
- HUYA Japan to Transfer Hiyasta Marketing Authorization to Meiji
December 1, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…